Streetbeat News

Analyst Ratings

XEL

BMO Capital analyst James Thalacker has downgraded Xcel Energy (NASDAQ:XEL) from Outperform to Market Perform.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 2:09 pm

SPB

Wells Fargo analyst Chris Carey reiterates an Overweight rating on Spectrum Brands Holdings (NYSE:SPB) and raises the price target from $85 to $90.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 2:07 pm

KHC

Wells Fargo analyst Chris Carey has reiterated an Equal-Weight rating on Kraft Heinz (NASDAQ:KHC) and lowered the price target from $44 to $40.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 2:06 pm

CSGS

Northland Capital Markets analyst Nehal Chokshi initiates coverage on CSG Systems Intl (NASDAQ:CSGS) with an Outperform rating and a price target of $82.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 2:06 pm

CNTA

Evercore ISI Group analyst Umer Raffat initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with an Outperform rating.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 2:05 pm

AVTR

In the last quarter, Avantor (NYSE:AVTR) received 6 somewhat bullish analyst ratings with an average 12-month price target of $25.33, down 8.22% from the previous average of $27.60.

Portfolio Pulse from Benzinga Insights

June 21, 2023 | 2:05 pm

SPB

Over the past 3 months, 6 analysts have published their opinion on Spectrum Brands Holdings (NYSE:SPB) stock, with an average 12-month price target of $85.5. The average price target has increased by 6.54% over the past month.

Portfolio Pulse from Benzinga Insights

June 21, 2023 | 2:04 pm

SPR

In the last 3 months, 7 analysts have offered 12-month price targets for Spirit AeroSystems Hldgs (NYSE:SPR), with an average price target of $33.0, a 12.23% decrease from the previous average price target of $37.60.

Portfolio Pulse from Benzinga Insights

June 21, 2023 | 2:03 pm

PTON

In the last 3 months, 11 analysts have offered 12-month price targets for Peloton Interactive (NASDAQ:PTON), with an average price target of $10.86, representing a 34.85% decrease from the previous average of $16.67.

Portfolio Pulse from Benzinga Insights

June 21, 2023 | 2:02 pm

XENE

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Xenon Pharmaceuticals (NASDAQ:XENE) and maintained a $58 price target.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 2:01 pm